The field of cancer immunology has witnessed dramatic progress with the advent of immunotherapies targeting the tumor immune microenvironment (TIME).

Interrupting one function of a protein that plays a key role in cell signaling could enable the development of new cancer treatments, according to a study led by Dr. Martin Taylor at the Warren Alpert ...

Georgetown University's Lombardi Comprehensive Cancer Center researchers have identified a new way to reprogram T cells, ...

From the deep sea to the shallow seafloor, researchers are uncovering unusual sugars that do something extraordinary to ...

Researchers have identified a new way to reprogram T cells, which are infection and tumor-fighting white blood cells, so that they have a superior memory, thereby making them more effective in killing ...

A new study explains how pancreatic tumors use a sugar coating to hide from the immune system and shows that a newly ...

Druggable phosphatases in cancer and immune cells, with examples of their corresponding drugs. Structures of allosteric inhibitors targeting PP2A, PRL3, DUSP1/6, and SHP2 in cancer cells (left).

QIMR Berghofer-led research in collaboration with Australian oncology company Kazia Therapeutics has found that combining the drug candidate paxalisib with immunotherapy triggered a molecular ...

As multi-cancer early detection (MCED) testing gains momentum, experts are honing their focus on what comes next for patients with a positive MCED test result. Understanding the diagnostic pathways ...

JCO Precision Oncology Conversations features discussions with leading authors of JCO Precision Oncology articles, hosted by Dr. Abdul Rafeh Naqash. Join our experts in engaging conversations as they ...